Sensei Biotherapeutics Inc. released a transaction and company overview presentation outlining its acquisition of Faeth Therapeutics, structured as a stock-for-stock exchange involving Sensei common stock and newly created Series B non-voting convertible preferred stock. The presentation also describes a concurrent $200 million private placement with institutional accredited investors. The company highlights planned use of proceeds to advance Faeth’s PIKTOR program (serabelisib + sapanisertib), including anticipated Phase 2 topline data in endometrial cancer and initiation of a Phase 1b trial in HR+/HER2- advanced breast cancer, both targeted by year-end 2026. The presentation also notes continuing leadership roles for Chris Gerry, Josiah Craver and Anand Parikh, with Parikh joining the board. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.